BioRegion Real Estate

Premium

Sanofi-aventis Kicks Off €200M Conversion of French Pharma Plant into Biotech Facility

Sanofi-aventis said this week it will spend €200M ($266 million) to transform its pharmaceuticals production site in Vitry-sur-Seine, France, into a facility for researching, developing, then producing biotechnology products through alliances with smaller biotech companies. Starting in 2012, for example, the plant is expected to create the company’s first cell culture biotechnoloy platform designed to produce monoclonal antibodies.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.